Latanoprost-Optik, eye drops 0.005% 5 ml

Pharmacotherapeutic group:

Antiglaucoma agent – prostaglandin F2α analogue synthetic

ATX code:
S01EE01

Pharmacological properties

Pharmacodynamics

Latanoprost, an analogue of prostaglandin F2α, is a selective agonist of FP (prostaglandin F) receptors and decreases intraocular pressure (IOP) by increasing aqueous outflow, mainly by uveoscleral and trabecular network. IOP reduction starts about 3-4 hours after the drug is injected; the maximum effect is observed after 8-12 hours; the action lasts for at least 24 hours.

It was determined that latanoprost has no significant effect on aqueous humor production and hemato-ophthalmic barrier.

When used in therapeutic doses latanoprost has no significant pharmacological effect on cardiovascular and respiratory systems.

Pharmacokinetics

Latanoprost (molecular weight 432.58) is a prodrug esterified with isopropyl group, inactive; after hydrolysis to the acid form it becomes biologically active.

Absorption

The prodrug is well absorbed through the cornea and is completely hydrolyzed upon contact with aqueous moisture.

Distribution

Studies in humans have shown that the maximum concentration in aqueous humor is reached 2 hours after instillation. After instillation in monkeys, latanoprost is predominantly distributed in the anterior chamber of the eye, conjunctiva and eyelids. Only a small amount of latanoprost reaches the posterior chamber of the eye.

Biotransformation

The active form of latanoprost is practically not metabolized in the eye, but undergoes biotransformation in the liver.

Excretion

The plasma elimination half-life is 17 minutes.

Animal studies have shown that the major metabolites (1,2-dinor- and 1,2,3,4-tetranormetabolites) have no (or low) biological activity and are excreted mainly with the urine.

Children

Latanoprost exposure is approximately 2 times greater in children aged 3 to 12 years compared to adult patients and 6 times greater in children younger than 3 years.

However, the safety profile of the drug does not differ in children and adults. The time to reach the maximum plasma concentration of latanoprost acid is 5 minutes for all age groups. The elimination half-life of latanoprost acid in children is the same as in adults. At equilibrium concentration there is no cumulation of latanoprost acid in blood plasma.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Contraindications

High sensitivity to latanoprost or other components of the drug. Age under 1 year (efficacy and safety have not been established).

Cautions

Aphakia, pseudoaphakia with rupture of the posterior lens capsule; patients with risk factors for macular edema (cases of macular edema, including cystoid edema, have been described during treatment with latanoprost); inflammatory, neovascular glaucoma (due to insufficient experience with the drug); bronchial asthma; history of herpetic keratitis.

The drug should be avoided in patients with an active form of herpetic keratitis and recurrent herpetic keratitis, especially associated with taking prostaglandin F2α analogues. The drug should be used with caution in patients with risk factors for iritis/veitis.

There are limited data on the use of the drug in patients scheduled for cataract surgery.

In this group of patients the drug should be used with caution.

Side effects

Overdose

Pregnancy use

Similarities